Candel Therapeutics, Inc. (CADL) - Q2 2024 10-Q Summary
Business Context and Reporting Period
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing off-the-shelf viral immunotherapies for cancer treatment. The primary product candidates are CAN-2409 (adenovirus-based) and CAN-3110 (herpes simplex virus-based). This report covers the quarterly period ended June 30, 2024. The company is classified as an emerging growth company and a smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(22,237) | $(9,614) | $(30,458) | $(18,409) |
| Net Loss Per Share | $(0.74) | $(0.33) | $(1.03) | $(0.64) |
| Operating Expenses | $8,571 | $9,579 | $16,473 | $19,212 |
| Cash and Cash Equivalents | $21,454 | $35,413 | $21,454 | $35,413 |
| Total Debt (Current + Long-term) | $16,514 | $20,525 | $16,514 | $20,525 |
| Warrant Liability | $14,248 | $916 | $14,248 | $916 |
Note: Debt figures represent the net carrying amount of the term loan and other long-term debt. The warrant liability increased significantly due to fair value adjustments.
Material Changes vs. Prior Period
- Net Loss Expansion: The net loss for the three months ended June 30, 2024, increased by $12.6 million compared to the same period in 2023. This was primarily driven by a $13.3 million non-cash loss from the change in fair value of the warrant liability, compared to a $0.1 million gain in the prior year.
- Operating Expense Reduction: Total operating expenses decreased by $1.0 million (Q2) and $2.7 million (YTD) compared to the prior year periods. This reduction is attributed to a corporate restructuring in late 2023 that reduced the workforce by approximately 45%, leading to lower employee-related and clinical development costs.
- Liquidity Position: Cash and cash equivalents decreased by approximately $14.0 million during the six months ended June 30, 2024, primarily due to net cash used in operating activities of $14.6 million.
- Debt Repayment: The company made principal payments of $4.2 million on its term loan with Silicon Valley Bank during the first half of 2024.
Guidance, Outlook, and Risks
- Going Concern: Management has determined that substantial doubt exists regarding the company's ability to continue as a going concern for the one-year period following the issuance of these financial statements. The company expects to require additional funding to sustain operations beyond the first quarter of 2025.
- Clinical Milestones:
- CAN-2409 (Prostate Cancer): Topline data from the pivotal Phase 3 trial is expected in Q4 2024.
- CAN-2409 (NSCLC): Updated overall survival data is expected in Q1 2025. Recent data showed a median overall survival (mOS) of 20.6 months in patients with progressive disease despite immune checkpoint inhibitor therapy.
- CAN-2409 (Pancreatic Cancer): Updated data expected in Q1 2025. Interim data showed mOS of 28.8 months vs. 12.5 months in the control group.
- CAN-3110 (Glioma): Updated Phase 1b data from the repeat dosing arm (Arm C) is expected in H2 2024.
- Capital Raising: The company has an "at-the-market" (ATM) equity offering program. As of June 30, 2024, it had raised $3.6 million under this program. Subsequent to the quarter end (through August 5, 2024), an additional $4.1 million was raised.
- Compliance Risk: The filing discloses an internal investigation regarding the former CEO, Dr. Estuardo Aguilar-Cordova, concerning allegations of falsified sterility testing results and stability program deficiencies for CAN-2409. The company stated that trial participants were not placed at risk and clinical data integrity remains intact. Dr. Aguilar-Cordova resigned from the board in June 2024.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $21.5 million cash balance against the projected burn rate and the timeline for the next capital raise, given the "substantial doubt" going concern warning.
- Warrant Liability Volatility: Monitor the fair value of the $14.2 million warrant liability, as fluctuations in the stock price will directly impact reported net loss without affecting cash flow.
- Clinical Data Readouts: Confirm the timing and results of the Phase 3 prostate cancer trial (expected Q4 2024) and the NSCLC/Pancreatic cancer updates (expected Q1 2025), as these are critical for future valuation and funding.
- Compliance Status: Review any subsequent communications regarding the FDA's response to the stability testing and sterility testing issues disclosed in the filing.
- Debt Covenants: Assess the impact of the $16.5 million term loan obligations and the potential for additional debt or equity dilution required to meet repayment schedules maturing in 2026.